None of the listed vaccines are authorized yet for public use.
1. In a phase 3 trial, Sanofi-GSK’s omicron-fighting vaccine candidate achieved a 72 percent efficacy against the variant — which the CDC reports makes up 100 percent of the nation’s COVID-19 cases — according to a June 24 press release.
Overall, the booster candidate showed a 64.7 percent efficacy against symptomatic infection and a 75.1 percent efficacy in people recovering from COVID-19. The trial found a “favorable safety and tolerability profile.”
2. Moderna plans to deliver tens of millions of its bivalent vaccine booster candidate this fall. The company said in a June 22 press release its booster increased antibodies 5.4-fold against omicron’s “sister variants,” BA.4 and BA.5.
The vaccine-maker said it has shared data with regulators and has manufactured doses in anticipation of approval.
3. Sanofi-GSK’s COVID-19 booster candidate beat Pfizer’s results June 13, with Sanofi-GSK’s second generation resulting in 76.1 percent of study participants seeing at least a tenfold increase in neutralizing antibody titers. Pfizer’s booster came in second with 63.2 percent.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.